Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 3,662 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 3,662 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $31.34, for a total transaction of $114,767.08. Following the sale, the insider directly owned 19,798 shares in the company, valued at approximately $620,469.32. This represents a 15.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Thursday, December 4th, Barry Ticho sold 1,696 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total transaction of $52,355.52.
• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $61,729.10.
• On Tuesday, December 2nd, Barry Ticho sold 2,006 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $59,738.68.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total value of $152,545.32.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $30.87 on Friday. The business has a fifty day moving average of $29.03 and a 200 day moving average of $19.83. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. As a group, equities research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Ratings Changes

STOK has been the topic of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Finally, Needham & Company LLC boosted their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the 3rd quarter valued at approximately $41,000. BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period. Strs Ohio purchased a new position in Stoke Therapeutics in the third quarter valued at $150,000. Finally, Osaic Holdings Inc. increased its holdings in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after buying an additional 5,427 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.